Abstract
By inducing p53-dependent G2 arrest, the pretreatment with low concentrations of DNA damaging drugs (e.g., doxorubicin, DOX) can prevent cell death caused by microtubule-active drugs (e.g., paclitaxel, PTX), thus potentially permitting selective killing of p53-deficient cancer cells. However, DOX still protects a subset of tumor cell lines lacking wt p53 (HL60 and Jurkat leukemia cells), thus limiting the utility of protection of cells with wt p53 (e.g., normal cells). The present work overcomes this obstacle by adding an abrogator of p53-independent checkpoint (e.g., UCN-01) to the DOX-PTX sequence. By inhibiting a p53-independent pathway, UCN-01 overrode DOX-induced G2 arrest and instead induced G1 arrest in HL60 and Jurkat, thus propelling these p53-deficient cells from G2 to G1. Once they entered mitosis, cells were killed by PTX. Induction of G2 arrest with sequential abrogation of a p53-independent checkpoint allows pharmacological manipulation of Raf-1/Bcl-2 hyperphosphorylation, PARP and Rb cleavage and cell death caused by PTX in p53-deficient cells. Unlike previous approaches, this strategy is intended to increase selectivity, not the cytotoxicity of PTX. This rational sequence of agents that induces p53-dependent and abrogates p53-independent arrest represents a cancerselective strategy for treatment of p53-deficient tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
An WG, Hwang SG, Trepel JB, Blagosklonny MV . 2000 Leukemia 14: 1276–1283
Blagosklonny MV . 1999 Leukemia 13: 2031–2035
Blagosklonny MV . 2001 Leukemia 15: 869–874
Blagosklonny MV, Dixon SC, Robey R, Figg WD . 2001 Int. J. Oncol. 19: 257–262
Blagosklonny MV, Pardee AB . 2001 Cancer Res. 61: 4301–4305
Blagosklonny MV, Robey R, Bates S, Fojo T . 2000 J. Clin. Invest. 105: 533–539
Blagosklonny MV, Robey R, Sheikh MS, Fojo T . 2002 Cancer Biol. Ther. 1: 113–117
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B . 1998 Science 282: 1497–1501
Busby EC, Leistritz DF, Abraham RT, Karnitz LM, Sarkaria JN . 2000 Cancer Res. 60: 2108–2112
Chan TA, Hwang PM, Hermeking H, Kinzler KW, Vogelstein B . 2000 Genes Dev. 14: 1584–1588
Chang BD, Xuan Y, Broude EV, Zhu H, Schott B, Fang J, Roninson IB . 1999 Oncogene 18: 4808–4818
Giannakakou P, Robey R, Fojo T, Blagosklonny MV . 2001 Oncogene 20: 3806–3813
Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, Piwnica-Worms H . 2000 J. Biol. Chem. 275: 5600–5605
Hu B, Zhou XY, Wang X, Zeng ZC, Iliakis G, Wang Y . 2001 J. Biol. Chem. 276: 17693–17698
Jordan MA, Wilson L . 1998 Curr. Opin. Cell Biol. 10: 123–130
Kastan MB, Canman CE, Leonard CJ . 1995 Cancer Metastasis Rev. 14: 3–15
Lau CC, Pardee AB . 1982 Proc. Natl. Acad. Sci. USA 79: 2942–2946
Li W, Fan J, Banerjee D, Bertino JR . 1999 Mol. Pharmacol. 55: 1988–1993
Passalaris TM, Benanti JA, Gewin L, Kiyono T, Galloway DA . 1999 Mol. Cell. Biol. 19: 5872–5881
Rowinsky EK, Donehower RC . 1995 N. Engl. J. Med. 332: 1004–1014
Sherr CJ . 2002 Cell Cycle 1: 36–38
Smith APL, Gimenez-Abian JF, Clarke DJ . 2002 Cell Cycle 1: 16–33
Torres K, Horwitz SB . 1998 Cancer Res. 58: 3620–3626
Vogelstein B, Lane D, Levine A . 2000 Nature 408: 307–310
Waldman T, Lengauer C, Kinzler KW, Vogelstein B . 1996 Nature 381: 643–644
Yu L, Orlandi L, Wang P, Orr MS, Senderowicz AM, Sausville EA, Silvestrini R, Watanabe N, Piwnica-Worms H, O'Connor PM . 1998 J. Biol. Chem. 273: 33455–33464
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Blagosklonny, M. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 21, 6249–6254 (2002). https://doi.org/10.1038/sj.onc.1205793
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205793
Keywords
This article is cited by
-
Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer
British Journal of Cancer (2020)
-
Inhibition of the histone demethylase, KDM5B, directly induces re-expression of tumor suppressor protein HEXIM1 in cancer cells
Breast Cancer Research (2019)
-
Combination therapy with p53–MDM2 binding inhibitors for malignancies
Medicinal Chemistry Research (2015)
-
p53-Based cyclotherapy: exploiting the ‘guardian of the genome’ to protect normal cells from cytotoxic therapy
British Journal of Cancer (2013)
-
Checkpoint kinase 1 in DNA damage response and cell cycle regulation
Cellular and Molecular Life Sciences (2013)